Arcutis Biotherapeutics, Inc.
ARQT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $47 | $73 | $53 | $71 |
| Short-Term Investments | $144 | $118 | $145 | $157 |
| Receivables | $115 | $107 | $85 | $73 |
| Inventory | $22 | $16 | $17 | $15 |
| Other Curr. Assets | $21 | $19 | $24 | $20 |
| Total Curr. Assets | $349 | $333 | $324 | $336 |
| Property Plant & Equip (Net) | $6 | $3 | $3 | $3 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $15 | $16 | $17 | $9 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $1 |
| Total NC Assets | $22 | $20 | $20 | $13 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $371 | $352 | $344 | $349 |
| Liabilities | – | – | – | – |
| Payables | $6 | $15 | $25 | $14 |
| Short-Term Debt | $1 | $1 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $93 | $88 | $66 | $66 |
| Total Curr. Liab. | $100 | $104 | $91 | $81 |
| LT Debt | $5 | $109 | $110 | $110 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $108 | $0 | $0 | $1 |
| Total NC Liab. | $113 | $110 | $110 | $110 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $2 | $3 | $3 |
| Total Liabilities | $213 | $213 | $201 | $191 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,155 | -$1,163 | -$1,147 | -$1,122 |
| AOCI | -$0 | -$0 | -$0 | -$0 |
| Other Equity | $1,314 | $1,302 | $1,290 | $1,279 |
| Total Equity | $158 | $139 | $143 | $158 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $371 | $352 | $344 | $349 |
| Net Debt | -$41 | $37 | $58 | $39 |